Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Twist Bioscience Corp (NASDAQ: TWST) closed at $34.34 up 6.02% from its previous closing price of $32.39. In other words, the price has increased by $6.02 from its previous closing price. On the day, 1.34 million shares were traded. TWST stock price reached its highest trading level at $35.15 during the session, while it also had its lowest trading level at $32.53.
Ratios:
For a deeper understanding of Twist Bioscience Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on November 04, 2025, initiated with a Overweight rating and assigned the stock a target price of $41.
On December 13, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.Guggenheim initiated its Buy rating on June 04, 2024, with a $53 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 22 ’25 when Green Paula sold 273 shares for $34.56 per share. The transaction valued at 9,434 led to the insider holds 166,639 shares of the business.
Cho Dennis sold 324 shares of TWST for $11,196 on Dec 22 ’25. The insider now owns 144,680 shares after completing the transaction at $34.56 per share. On Dec 22 ’25, another insider, Leproust Emily M., who serves as the Chief Executive Officer of the company, sold 1,605 shares for $34.56 each. As a result, the insider received 55,462 and left with 874,313 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 2099823104 and an Enterprise Value of 1957961216. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.58 while its Price-to-Book (P/B) ratio in mrq is 4.40. Its current Enterprise Value per Revenue stands at 5.199 whereas that against EBITDA is -17.129.
Stock Price History:
The Beta on a monthly basis for TWST is 2.23, which has changed by -0.29000437 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $23.30. The 50-Day Moving Average of the stock is 9.72%, while the 200-Day Moving Average is calculated to be 5.97%.
Shares Statistics:
For the past three months, TWST has traded an average of 1.60M shares per day and 995560 over the past ten days. A total of 60.63M shares are outstanding, with a floating share count of 58.32M. Insiders hold about 4.62% of the company’s shares, while institutions hold 116.81% stake in the company. Shares short for TWST as of 1765756800 were 13742759 with a Short Ratio of 8.58, compared to 1763078400 on 10898965. Therefore, it implies a Short% of Shares Outstanding of 13742759 and a Short% of Float of 25.319999999999997.
Earnings Estimates
A comprehensive evaluation of Twist Bioscience Corp (TWST) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.47 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$2.47 and -$2.47 for the fiscal current year, implying an average EPS of -$2.47. EPS for the following year is -$2.05, with 1.0 analysts recommending between -$2.05 and -$2.05.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $100.3M this quarter.It ranges from a high estimate of $101M to a low estimate of $100M. As of. The current estimate, Twist Bioscience Corp’s year-ago sales were $88.71MFor the next quarter, 8 analysts are estimating revenue of $104.33M. There is a high estimate of $105.5M for the next quarter, whereas the lowest estimate is $103.85M.
A total of 9 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $431.96M, while the lowest revenue estimate was $428.92M, resulting in an average revenue estimate of $429.98M. In the same quarter a year ago, actual revenue was $376.57MBased on 9 analysts’ estimates, the company’s revenue will be $495.67M in the next fiscal year. The high estimate is $503.8M and the low estimate is $485.63M.
